Healthcare with Confidence
A Patient-Friendly Guide + Next Steps
Immunotherapy has changed how many people with esophageal cancer (and gastroesophageal junction/GEJ cancer) are treated—especially when the disease is advanced or when there’s a risk it could come back after surgery.
Israel’s major cancer centers use the same evidence-based approaches used internationally, access to genomic profiling for GI tumors (including esophageal/GEJ) and added certain therapies for these cancers in specific indications.
What is immunotherapy (in simple terms)?
Most esophageal cancer immunotherapy today means immune checkpoint inhibitors—medicines that “take the brakes off” your immune system so it can recognize and attack cancer cells.
The most commonly used checkpoint inhibitors for esophageal/GEJ cancers worldwide include drugs targeting PD-1/PD-L1, such as nivolumab and pembrolizumab.
When is immunotherapy used for esophageal cancer?
Your treatment plan depends on:
- Cancer type: squamous cell carcinoma vs adenocarcinoma
- Stage: localized vs locally advanced vs metastatic
- Biomarkers: PD-L1, MSI/MMR, HER2 (mainly for adenocarcinoma), and others
- Your overall health and kidney/liver/lung function
After chemoradiation + surgery (adjuvant setting)
If you had neoadjuvant chemoradiotherapy followed by surgery, and the pathology shows residual cancer, adjuvant nivolumab can reduce the risk of recurrence and extend disease-free survival. This approach is supported by the phase 3 CheckMate 577 trial.
First-line treatment for advanced/metastatic disease
For many patients with unresectable or metastatic esophageal/GEJ cancer, immunotherapy is used together with chemotherapy from the start (depending on tumor type and biomarkers). Examples include:
- Pembrolizumab + platinum/fluoropyrimidine chemotherapy (KEYNOTE-590 basis)
- Nivolumab + chemotherapy or nivolumab + ipilimumab for advanced ESCC (CheckMate-648 basis)
- Nivolumab + chemotherapy is also a key option in advanced gastric/GEJ/esophageal adenocarcinoma regimens (CheckMate-649). Long-term follow-up continues to support benefit in appropriate patients.
Later-line options and special biomarker cases
If the cancer progresses after initial therapy, immunotherapy may still be used—especially in tumors with certain features (for example MSI-H/dMMR), or through clinical trials.
What’s new in Israel that patients should know
Israel’s updates reported by local health sources include:
- Genomic profiling tests for GI tumors to help match patients to advanced treatments (this includes esophageal and GEJ cancers).
- New/expanded therapies for esophageal, gastric and GEJ cancers in specific indications (including immunotherapy agents listed for these cancers).
Practical meaning: more patients may be able to access molecular testing and modern drug options through Israel’s system (eligibility still depends on the exact indication and the rules of the basket/HMO).
Tests to ask for before starting immunotherapy
A good Israeli esophageal cancer team typically reviews:
- Pathology confirmation (type: ESCC vs adenocarcinoma)
- PD-L1 score (often CPS)
- MSI/MMR status
- For adenocarcinoma: HER2 (and sometimes broader genomic profiling)
- Staging: CT/PET-CT, endoscopy reports, biopsy results
Because Israel’s updates emphasize genomic profiling in GI cancers, it’s worth asking whether comprehensive profiling is appropriate for your exact case.
Side effects: what patients should watch for
Immunotherapy side effects are often different from chemo. Many people feel OK, but some develop immune-related inflammation, which can affect organs such as:
- Skin (rash/itching)
- Thyroid (fatigue, weight change)
- Gut (diarrhea/colitis)
- Liver (hepatitis—often seen only on labs)
- Lungs (new cough/shortness of breath)
Key rule: report new symptoms early, even if they seem minor—most immune side effects are manageable when treated promptly.
Why patients choose Israel for immunotherapy-based care
Many patients seek care in Israel because large centers offer:
- Multidisciplinary teams (GI oncology + radiation oncology + thoracic/upper-GI surgery + pathology)
- Access to international-standard regimens and clinical trials
- Increasing use of molecular testing in GI cancers
Get an immunotherapy-focused second opinion in Israel
If you want a clear plan from an Israeli esophageal cancer team, prepare and send:
- Pathology report + immunohistochemistry (PD-L1, MSI/MMR, HER2 if done)
- Endoscopy report + biopsy details
- Imaging reports (CT/PET-CT) + scan files if available
- Treatment summary (chemo/radiation/surgery dates and regimens)
- Current symptoms + medication list
